Document ID: chunk:federal_register_of_legislation:F2025L00212:clause:1_5071
Version: federal_register_of_legislation:F2025L00212
Segment Type: clause
Provision Reference: sch 1 cl 5071
Character Range: 2360177–2361429

5071                                      UBIDECARENONE                                  A, E      When used as an excipient, the route of administration must be topical and the concentration in the medicine must not be more than 0.05%.
                                                                                                   Not to be included in medicines intended for use in the eye.
                                                                                                   When for internal use, the maximum recommended daily dose must not provide more than 300 milligrams of ubidecarenone.
                                                                                                   When for internal use in combination with Ubiquinol-10, the maximum recommended daily dose must not provide more than 300 milligrams of ubiquinol-10 and ubidecarenone combined.
                                                                                                   When for internal use, the following warning statement is required on the medicine label:
                                                                                                   - (WARF) 'Do not take while on warfarin therapy without medical advice'.